Multigene prognostic assay for lung cancer

摘要

The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.

主权项

1. A method of treating a subject having stage I non-small cell lung cancer (NSCLC), based on a prognosis, the method comprising the steps of:
(a) contacting a biological sample from the subject with assay reagents that specifically bind to at least eleven biomarkers, wherein the eleven biomarkers consist of BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A; (b) determining the levels of mRNA expression of the biomarkers in the sample using a quantitative PCR assay; (c) determining a risk score of the subject based on the levels of mRNA expression of the biomarkers in the sample; (d) using the risk score to provide a prognosis for the subject, wherein the risk score is indicative of said prognosis, and wherein the prognosis provides a low risk assessment or a high risk assessment; and (e) treating the subject having a high risk assessment with adjuvant chemotherapy.